Regístrese
Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Expression of miR-22 and miR-150 in type 1 diabetes mellitus: Possible relations...
Journal Information
Vol. 147. Issue 6.
Pages 245-247 (September 2016)
Share
Share
Download PDF
More article options
ePub
Visits
0
Vol. 147. Issue 6.
Pages 245-247 (September 2016)
Brief report
DOI: 10.1016/j.medcle.2016.10.014
Expression of miR-22 and miR-150 in type 1 diabetes mellitus: Possible relationship with autoimmunity and clinical characteristics
Expresión de miR-22 y miR-150 en diabetes mellitus tipo 1: posible asociación con autoinmunidad y características clínicas de la enfermedad
Visits
0
Santiago Estrellaa, Diego F. Garcia-Diaza, Ethel Codnerb, Patricia Camacho-Guilléna, Francisco Pérez-Bravoa,
Corresponding author
fperez@med.uchile.cl

Corresponding author.
a Laboratorio de Nutrigenómica, Departamento de Nutrición, Facultad de Medicina, Universidad de Chile, Santiago, Chile
b Instituto de Investigaciones Materno Infantil (IDIMI), Hospital San Borja Arriarán, Facultad de Medicina, Universidad de Chile, Santiago, Chile
This item has received
0
Visits
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (1)
Table 1. Clinical parameters and distribution of autoantibodies of patients with DM1 and controls.
Abstract
Background and objective

Type 1 diabetes (T1D) is an autoimmune disease of complex aetiology. Several microRNAs (miR) have been linked to the pathogenesis of autoimmune diseases.

To analyze the possible association of miR-22 and miR-150 with autoimmunity and clinical severity of T1D.

Patients and methods

The study was performed in peripheral blood mononuclear cells of 20 patients with T1D and 20 control subjects. The expression of miR-22 and miR-150 was performed in peripheral blood mononuclear cells using TaqMan probes to different glucose concentrations (baseline, 11mm, 25mm).

Results

Our results suggest that the expression of miR-22 is increased in T1D patients compared to the controls. This effect was observed in baseline glucose conditions and decreased in 11 and 25mM of glucose. The expression of miR-150 was lower in T1D patients versus the controls. There was no correlation between the autoimmune profile and the two studied miRNAs. miR-22 (baseline condition) and miR-150 (11mM condition) or the ketoacidosis component.

Conclusion

miR-22 and 150 were not associated with the autoimmune component present in T1D patients.

Keywords:
miR-22
miR-150
Type 1 diabetes
Autoimmunity
Resumen
Introducción

La diabetes tipo 1 (DM1) es una enfermedad autoinmune de etiología compleja. Diversos microARN (miR) han sido relacionados con la patogénesis de enfermedades autoinmunes.

Objetivo

Analizar la posible asociación de miR-22 y miR-150 con autoinmunidad y gravedad clínica en la DM1.

Pacientes y método

El estudio se realizó en células mononucleares periféricas de 20 pacientes con DM1 y 20 sujetos controles. La expresión de miR-22 y miR-150 se realizó por sondas TaqMan en células mononucleares periféricas a diferentes concentraciones de glucosa (basal, 11mM, 25mM).

Resultados

Nuestros resultados muestran que la expresión de miR-22 está aumentada en pacientes con DM1 respecto de controles. Este efecto se observó en la condición basal de glucosa y disminuyó en condiciones 11 y 25mM de glucosa. La expresión de miR-150 fue menor en pacientes con DM1 versus controles. No hubo asociación de los niveles de miR-22 (condición basal) y miR-150 (condición 11mM) con el perfil de autoinmunidad ni la presencia de cetoacidosis.

Conclusión

miR-22 y miR-150 no se asocian a los niveles de autoanticuerpos, pero sí al componente de cetoacidosis en DM1.

Palabras clave:
miR-22
miR-150
Diabetes tipo 1
Autoinmunidad

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.